Image

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML

Recruiting
18 years of age
Both
Phase 2

Powered by AI

Overview

Tamibarotene is being studied as a treatment for participants with a type of leukemia called acute myeloid leukemia, or AML for short. Tamibarotene is being studied as a treatment for participants with AML whose cancer has a specific genetic abnormality characterized by the overexpression of the retinoic acid receptor alpha (RARA) gene. This genetic profile is found in about 3 of every 10 people with AML.

During the trial, tamibarotene will be given with 2 other drugs that are already used together to treat people who have AML and who cannot start treatment with standard chemotherapy.

Description

This study consists of 3 parts. In Part 1, the safety, tolerability, and pharmacokinetic (PK) evaluation of tamibarotene/venetoclax/azacitidine combination will inform the appropriate tamibarotene dose to be combined with the standard of care (SOC) venetoclax/azacitidine in Part 2 and Part 3. In Part 2, participants will be randomized 1:1 to receive either tamibarotene/venetoclax/azacitidine or venetoclax/azacitidine to compare the clinical activity of the 2 combinations. In Part 3, tamibarotene will be added to the venetoclax/azacytidine regimen of a subset of Part 2 participants who experience progressive disease, relapse after initial complete remission (CR) or CR with incomplete blood count recovery (CRi) response, or treatment failure.

Eligibility

Note: all inclusion/exclusion criteria should be met prior to the first dose of

        venetoclax/azacitidine on Cycle 1 Day 1 with the exception of the RARA-biomarker test
        result referenced in inclusion criterion 2, which should be positive by Cycle 1 Day 8 to
        continue treatment on study.
        Inclusion Criteria:
          -  All participants must have obtained a blood sample for RARA biomarker investigational
             assay testing prior to starting treatment on Cycle 1 Day 1. The results of the
             investigational biomarker assay for all participants must be confirmed as
             RARA-positive by Cycle 1 Day 8 to enroll (Part 1) or to be randomized (Part 2) in the
             study.
          -  Participants must have newly diagnosed, previously untreated non-acute promyelocytic
             leukemia (APL) AML with a bone marrow or peripheral blood blast count ≥20% and must be
             unlikely to tolerate standard intensive chemotherapy at the time of Cycle 1 Day 1
             Visit due to age, performance status, or comorbidities based on at least one of the
             following criteria:
               -  age ≥75 years old, or
               -  age <75 years old, with at least one of the following:
                    -  Eastern Cooperative Oncology Group (ECOG) performance status of 3
                    -  cardiac history of congestive heart failure (CHF) or documented ejection
                       fraction (EF) ≤50%
                    -  pulmonary disease with diffusing capacity of the lungs for carbon monoxide
                       (DLCO) ≤65% or forced expiratory volume in one second (FEV1) ≤65%
                    -  creatinine clearance ≥30 milliliters (mL)/minute (min) to <45 mL/min based
                       on the Cockcroft-Gault glomerular filtration rate estimation
                    -  hepatic impairment with total bilirubin >1.5 to ≤3.0 * upper limit of normal
                       (ULN)
                    -  any other comorbidity that the investigator judges to be incompatible with
                       intensive chemotherapy, and reviewed and approved by the sponsor.
        Exclusion Criteria:
          -  Participants have APL.
          -  Participants have known active central nervous system involvement with AML.
          -  Prior treatment (before Cycle 1 Day 1) for the diagnosis of AML, myelodysplastic
             syndromes (MDS), or antecedent hematologic malignancy with any hypomethylating agent,
             venetoclax, chemotherapy, or hematopoietic stem cell transplantation (HSCT), with the
             exception of prior treatment with hydroxyurea.

Study details

Acute Myeloid Leukemia

NCT04905407

Syros Pharmaceuticals

15 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.